Tay-Sachs disease is inherited in an autosomal recessive pattern, meaning a child must receive one copy of a mutated gene from each parent to develop the condition. Both parents can be perfectly healthy carriers with no symptoms, each carrying one working copy and one faulty copy of the gene. When two carriers have a child together, there is a 25% chance the child will have Tay-Sachs, a 50% chance the child will be a carrier like the parents, and a 25% chance the child will inherit no mutations at all.
The Gene Behind Tay-Sachs
The disease traces to mutations in a single gene called HEXA, located on chromosome 15. This gene provides instructions for making an enzyme that breaks down a fatty substance called GM2 ganglioside in the brain. More than 210 different mutations in the HEXA gene have been identified that can cause Tay-Sachs. Most of these mutations produce a completely nonfunctional version of the enzyme, while others severely reduce its activity without eliminating it entirely.
Carriers have one working copy of HEXA and one mutated copy. That single working copy produces enough of the enzyme to keep the brain functioning normally, which is why carriers never develop symptoms. But when a child inherits two broken copies, one from each parent, their cells produce little to no functional enzyme. GM2 ganglioside, normally present in neurons in very small quantities, begins to accumulate inside brain and nerve cells. This buildup progressively damages and destroys neurons, leading to the neurological decline that defines the disease.
How the Odds Work for Carrier Parents
Every pregnancy between two carriers is an independent event with the same probabilities: a 1 in 4 chance of Tay-Sachs, a 2 in 4 chance of being a carrier, and a 1 in 4 chance of inheriting two normal copies. These odds reset with each pregnancy. Having one affected child does not change the probability for future children.
If only one parent is a carrier, none of their children will develop Tay-Sachs. However, each child will have a 50% chance of being a carrier themselves, which becomes relevant when they eventually have their own children.
Populations With Higher Carrier Rates
Tay-Sachs can occur in any ethnic group, but certain populations carry the mutation at significantly higher rates. Among Ashkenazi Jews (those of Central and Eastern European descent), roughly 1 in 27 people is a carrier. French Canadians and Cajun Americans carry the mutation at a similar rate of about 1 in 27. Irish Americans also have an elevated carrier frequency, estimated at about 1 in 50. By comparison, the general population has a carrier rate of roughly 1 in 250.
These elevated rates are thought to result from “founder effects,” where small, historically isolated communities happened to include carriers among their founding members. Over generations, the mutation became more common within those groups than it is in the broader population.
Infantile vs. Late-Onset Forms
The inheritance pattern is the same regardless of which form of Tay-Sachs a person develops, but the specific mutations involved determine severity. The classic infantile form, which is the most severe, occurs when a child inherits two “null” mutations that completely shut down enzyme production. Symptoms typically appear within the first few months of life.
Late-onset Tay-Sachs (LOTS) follows the same autosomal recessive pattern but involves at least one mutation that allows a small amount of enzyme activity to persist. A person with LOTS often carries one severe mutation and one milder, adult-onset mutation. Because symptoms may not appear until the teens or even adulthood, and because the milder mutations are not always included in standard screening panels, the risk of passing on LOTS can go undetected unless more comprehensive genetic testing is done.
Carrier Screening and Testing Options
Because carriers show no symptoms, the only way to know your carrier status is through testing. The American College of Obstetricians and Gynecologists recommends that information about carrier screening be provided to every pregnant woman, and ideally that screening happen before pregnancy so couples can understand their reproductive options early.
Two types of tests are available. The first and most widely used is an enzyme activity test, which measures how much functional enzyme your blood cells produce. It has a sensitivity of about 97 to 98% and can detect carriers regardless of which specific mutation they have. The second is a DNA-based test that looks for known mutations in the HEXA gene directly. This test is slightly less sensitive (around 95%) because it can only identify mutations that have already been cataloged. If your enzyme test comes back inconclusive, DNA testing can help clarify the result. DNA testing is also useful for identifying pseudodeficiency alleles, which are gene variants that look abnormal on an enzyme test but do not actually cause disease.
For couples who are both confirmed carriers and become pregnant, prenatal diagnosis is possible. Testing can be performed by sampling a tiny piece of the placenta (chorionic villus sampling) or by drawing a small amount of the fluid surrounding the baby (amniocentesis). These tests can determine whether the developing baby has inherited two mutated copies of the gene.